Dépistage et prévention de l'infection par le VIH à Mayotte

Si Mayotte semble relativement épargnée comme les autres îles de l'océan indien par l'infection à VIH, il n'existe cependant aucune donnée de séroprévalence...Devant le contexte sociodémographique et les spécificités du système de soins à Mayotte, le dépistage et la prise en charge des patients vivants avec le VIH présente certaines particularités. L'objectif de cette ètude est de mettre en évidence les particularités de l'épidémie de VIH/Sida et de prise en charge des PVVIH à Mayotte à travers une analyse descriptive, rétrospective des données des patients suivis de 1990 à 2010 au sein du Centre hospitalier de Mayotte. On note une augmentation progressive du nombre de nouveaux cas de patients séropositifs au fur et à mesure des années. Une des caractérisques de l'épidémie de VIH/Sida à Mayotte est le nombre important de perdus de vue. Des études de séroprévalence couplées à des enquêtes socio-comportementales devraient permettre de mieux cibler les axes de prévention à privilégier.RENNES1-BU Santé (352382103) / SudocSudocFranceF

La santé à Mayotte (particularités du système de soins et de l'exercice de la médecine générale)

RENNES1-BU Santé (352382103) / SudocSudocFranceF

Bilan des activités du centre antituberculeux de Mayotte, deux années après sa mise en place

BORDEAUX2-BU Santé (330632101) / SudocSudocFranceF

Diphtheria in Mayotte, 2007–2015

Epidemiology of diphtheria in the southwestern Indian Ocean is poorly documented. We analyzed 14 cases of infection with toxigenic Corynebacterium diphtheriae reported during 2007–2015 in Mayotte, a French department located in this region. Local control of diphtheria is needed to minimize the risk for importation of the bacterium into disease-free areas

Diphtheria in Mayotte, 2007–2015

International audienceEpidemiology of diphtheria in the southwestern Indian Ocean is poorly documented. We analyzed 14 cases of infection with toxigenic Corynebacterium diphtheriae reported during 2007–2015 in Mayotte, a French department located in this region. Local control of diphtheria is needed to minimize the risk for importation of the bacterium into disease-free areas

Outbreak of IMI-1 carbapenemase-producing colistin-resistant Enterobacter cloacae on the French island of Mayotte (Indian Ocean)

International audienceThe spread of carbapenemase-producing Enterobacteriaceae in the Southwest Indian Ocean islands is poorly known. Here we describe an outbreak of colistin-resistant Enterobacter cloacae harbouring blaIMI-1 in the French overseas department of Mayotte. Between October 2015 and January 2017, all isolates of imipenem-non-susceptible E. cloacae at Mayotte Medical Center and University Hospital of Reunion Island were screened for carbapenemase production. Positive isolates were typed by pulsed-field gel electrophoresis and whole-genome sequencing (WGS)-based multilocus sequence typing (MLST), and all β-lactamase genes were identified by PCR and sequencing. Resistance profiles were determined by agar diffusion and Etest. Genetic support of the blaIMI-1 gene was determined by WGS. A total of 18 E. cloacae isolates harbouring blaIMI-1 were detected in 17 patients from Mayotte. Pulsed-field gel electrophoresis (PFGE) analysis showed 16 of the 18 strains to be clonally related and belonging to ST820. Based on clinical data, this outbreak most likely had a community origin. The blaIMI-1 gene in the 18 isolates was carried by a new variant of an integrative mobile element involving the Xer recombinases, called EcloIMEX-8. The mcr-1-mcr-5 genes were absent from the collection. The isolates belonged to E. cloacae cluster XI, known to be colistin heteroresistant. Here we report the first outbreak of IMI-1-producing Enterobacteriaceae. IMI-1-producers may be underdetected in microbiology laboratories because of their unusual antimicrobial resistance profile (resistant to imipenem but with intermediate resistance to ertapenem and susceptible to extended-spectrum cephalosporins) and the absence of blaIMI-1 in the panel of genes targeted by molecular diagnostic kits

Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF

BACKGROUND: Many patients with atrial fibrillation have concomitant coronary artery disease with or without acute coronary syndromes and are in need of additional antithrombotic therapy. There are few data on the long-term clinical outcome of atrial fibrillation patients with a history of acute coronary syndrome. This is a 2-year study of atrial fibrillation patients with or without a history of acute coronary syndromes